{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-033948","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.030091+00:00","generated_at":"2026-05-16T22:26:50.642665+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Monopar presents Phase 2 data showing ALXN1840 rapidly improves copper balance in Wilson disease","bullets":["Oral presentation at AASLD 2025: 'Rapidly Improved Cu Balance in Wilson Disease Patients on Tiomolybdate Choline.'","Mean daily copper balance significantly improved vs. pre-treatment baseline in 8 patients on ALXN1840.","Improvement observed during 15 mg once-daily (days 1-28) and entire treatment period (days 1-39).","Copper balance improved primarily via increased fecal copper excretion; data available on Monopar's website."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-033948","json":"https://secwatch.observer/filing/0001437749-25-033948.json","markdown":"https://secwatch.observer/filing/0001437749-25-033948.md","text":"https://secwatch.observer/filing/0001437749-25-033948.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925033948/0001437749-25-033948-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925033948/mnpr20251108_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:26:50.642665+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}